VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.81 Million in Lantheus Holdings, Inc. $LNTH

Key Points

• Virginia Retirement Systems invested approximately $1.81 million in Lantheus Holdings, acquiring 22,133 shares in the 2nd quarter.
• Insider Rajiv A. Patel sold 3.365 million shares of Lantheus stock, resulting in a 49.18% decrease in his position.
• Analyst ratings for Lantheus vary, with targets significantly reduced from previous highs; the average price target is now at $74.50, with several firms assigning a "Moderate Buy" rating.

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 22,133 shares of the medical equipment provider's stock, valued at approximately $1,812,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. State of Michigan Retirement System boosted its holdings in Lantheus by 0.6% in the 1st quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock valued at $1,620,000 after purchasing an additional 100 shares during the period. Signaturefd LLC raised its position in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares during the last quarter. Intrust Bank NA lifted its stake in shares of Lantheus by 2.9% in the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider's stock valued at $431,000 after buying an additional 125 shares during the period. Focus Financial Network Inc. increased its stake in Lantheus by 4.0% during the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider's stock valued at $293,000 after acquiring an additional 136 shares during the period. Finally, Nisa Investment Advisors LLC raised its holdings in Lantheus by 2.1% in the 1st quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock valued at $653,000 after acquiring an additional 139 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. JMP Securities decreased their price objective on Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Mizuho decreased their price target on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, August 7th. TD Cowen dropped their price objective on shares of Lantheus from $95.00 to $80.00 and set a "buy" rating for the company in a research note on Monday, September 15th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Lantheus in a report on Wednesday, October 8th. Finally, Truist Financial set a $63.00 target price on shares of Lantheus and gave the company a "hold" rating in a research note on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Lantheus presently has an average rating of "Moderate Buy" and a consensus price target of $74.50.

Insider Activity at Lantheus

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the business's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,812,000 shares of company stock worth $382,427,380 over the last three months. 1.50% of the stock is owned by company insiders.

Lantheus Stock Performance

Lantheus stock opened at $57.13 on Thursday. The firm has a market capitalization of $3.88 billion, a P/E ratio of 15.19 and a beta of 0.09. The stock has a fifty day moving average price of $54.06 and a two-hundred day moving average price of $72.51. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $118.21. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $92.51 million for the quarter. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.